Evidence map›Paper›PMID 27582220›Full record

ArticleNature2016

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling and 18 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,575 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,575citing papers in PubMed, 6 pooled it
155.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04250376 naunknown statusnot on this mapstarted 2017, after this paper: background citation

The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias

TypeinterventionalSponsorNeurological Associates of West Los AngelesRan2017 to 2025Enrolled100ConditionsMild Cognitive Impairment, Mild Dementia, Parkinson Disease, Alzheimer DiseaseArmsFocused Transcranial Ultrasound
NCT07680660 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Cervical Lymph Vessel/Node-venous Anastomosis Combined With Donepezil Versus Donepezil Alone in the Treatment of Alzheimer's Disease

TypeinterventionalSponsorShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityRan2026 to 2029Enrolled216ConditionsAlzheimer s DiseaseArmsCervical lymph vessel/node-venous anastomosis surgery combined with oral donepezil, Oral treatment with donepezil
3 · Its place in the literature

Who cites it

1,575 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,998 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

1,515 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 3 institutions in 2 countries.

Jeff SevignyBiogen, Cambridge, Massachusetts 02142, USA.
Ping ChiaoBiogen, Cambridge, Massachusetts 02142, USA.
Thierry BussièreBiogen, Cambridge, Massachusetts 02142, USA.
Paul H WeinrebBiogen, Cambridge, Massachusetts 02142, USA.
Leslie WilliamsBiogen, Cambridge, Massachusetts 02142, USA.
Marcel MaierNeurimmune, Schlieren-Zurich 8952, Switzerland.
Robert DunstanBiogen, Cambridge, Massachusetts 02142, USA.
Stephen SallowayButler Hospital, Providence, Rhode Island 02906, USA.
Tianle ChenBiogen, Cambridge, Massachusetts 02142, USA.
Yan LingBiogen, Cambridge, Massachusetts 02142, USA.
John O'GormanBiogen, Cambridge, Massachusetts 02142, USA.
Fang QianBiogen, Cambridge, Massachusetts 02142, USA.
Mahin ArastuBiogen, Cambridge, Massachusetts 02142, USA.
Mingwei LiBiogen, Cambridge, Massachusetts 02142, USA.
Sowmya ChollateBiogen, Cambridge, Massachusetts 02142, USA.
Melanie S BrennanBiogen, Cambridge, Massachusetts 02142, USA.
Omar Quintero-MonzonBiogen, Cambridge, Massachusetts 02142, USA.
Robert H ScannevinBiogen, Cambridge, Massachusetts 02142, USA.
H Moore ArnoldBiogen, Cambridge, Massachusetts 02142, USA.
Thomas EngberBiogen, Cambridge, Massachusetts 02142, USA.
Kenneth RhodesBiogen, Cambridge, Massachusetts 02142, USA.
James FerreroBiogen, Cambridge, Massachusetts 02142, USA.
Yaming HangBiogen, Cambridge, Massachusetts 02142, USA.
Alvydas MikulskisBiogen, Cambridge, Massachusetts 02142, USA.
Jan GrimmNeurimmune, Schlieren-Zurich 8952, Switzerland.
Christoph HockNeurimmune, Schlieren-Zurich 8952, Switzerland.
Roger M NitschNeurimmune, Schlieren-Zurich 8952, Switzerland.
Alfred SandrockBiogen, Cambridge, Massachusetts 02142, USA.
Biogen (United States) · USLight Chain Bioscience (Switzerland) · CHProvidence College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloidAmyloid beta-PeptidesAnimalsAntibodies, Monoclonal, HumanizedBrainClinical Trials, Phase III as TopicDisease Models, AnimalDose-Response Relationship, DrugFemaleHumansMaleMiceMice, TransgenicaducanumabAmyloidAmyloid beta-PeptidesAntibodies, Monoclonal, Humanized

Identifiers

PMID27582220
OpenAlexW2510806376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.